+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID06304441

Comparing Intra-pemetrexed Plus Osimertinib Versus Osimertinib Alone for Treating Leptomeningeal Metastasis in EGFR Mutation-Positive Non-Small-Cell Lung Cancer

Led by Guangzhou Medical University · Updated on 2025-09-29

100

Participants Needed

1

Research Sites

10 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the effects of combining intrathecal pemetrexed with third-generation small molecule tyrosine kinase inhibitors TKIs, such as osimertinib, versus TKIs alone in treating leptomeningeal metastasis in patients with epidermal growth factor receptor EGFR mutation-positive non-small cell lung cancer NSCLC. Intrathecal chemotherapy is a common treatment for leptomeningeal metastases, and osimertinib has shown promise in improving outcomes in this patient group. However, it remains unclear whether adding intrathecal pemetrexed to osimertinib offers additional benefits. Participants are randomly assigned to one of two groups one receives intrathecal pemetrexed combined with a third-generation TKI like osimertinib, while the other receives the TKI alone. Osimertinib is taken orally at a double dose of 160 mg daily until disease progression or intolerable side effects occur. Pemetrexed is delivered intrathecally with dexamethasone, starting with induction chemotherapy twice weekly for two weeks, then consolidation once weekly for four weeks, followed by monthly maintenance until progression or unacceptable toxicity. During the study, participants will be monitored for clinical response up to six months from randomization, with evaluations of disease progression and survival. Researchers will also track treatment-related side effects during this period. The study includes assessments of overall survival from enrollment until death or last follow-up, with a minimum follow-up of seven months. The total participation duration varies depending on disease progression and treatment tolerance.

CONDITIONS

Brief Title

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Research Team

Z

Zhenyu Pan

G

Guozi Yang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here